VoxNeuro Inc., a Hamilton based software-as-a-medical device company (SaMD), is partnering with Boston University, a global lead in neuroscience innovation, to research mild-Traumatic Brain Injury (mTBI)/Concussion and Alzheimer’s disease.
Both mTBI Concussion and Alzheimer’s disease affect millions of people annually and the inefficiency in the screening methodologies result in high costs and timing challenges for patients and the healthcare system at large. For the studies, VoxNeuro’s cognitive health assessment platform will analyze brain function using validated biomarkers and provide additional diagnostics than those derived by traditional testing methods.
VoxNeuro anticipates that the studies will progress the way clinicians diagnose and treat patients and highlight better management strategies. For example, clinicians using VoxNeuro’s technology may not require a research laboratory to diagnose Alzheimer’s.
This new research is expected to push the boundaries of brain health and may help drive the advancement of VoxNeuros’s second-generation products.